Phosphodiesterase 2 (PDE2) inhibitors: an updated patent review (2017–present)
- 9 October 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 34 (11) , 1105-1119
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82003652)
This publication has 56 references indexed in Scilit:
- Treatment with the selective PDE4B inhibitor A-33 or PDE4D inhibitor zatolmilast prevents sleep deprivation-induced deficits in spatial pattern separationBehavioural Brain Research, 2023
- Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitorsBioorganic Chemistry, 2021
- Discovery of effective phosphodiesterase 2 inhibitors with antioxidant activities for the treatment of Alzheimer’s diseaseBioorganic & Medicinal Chemistry Letters, 2021
- Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer’s Disease in MiceNeurochemical Research, 2021
- Apremilast: A Review in Psoriasis and Psoriatic ArthritisDrugs, 2017
- Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysisIntensive Care Medicine, 2016
- A new chemical tool for exploring the physiological function of the PDE2 isozymeBioorganic & Medicinal Chemistry Letters, 2006
- Eburnamine derivatives and the brainMedicinal Research Reviews, 2005
- Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159Archives of Pharmacal Research, 2000
- Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenineCellular Signalling, 1995